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A B S T R A C T
Purpose
Response criteria are well established for adult patients with non-Hodgkin lymphoma (NHL). A
revised set of response criteria in adults with NHL was recently published. However, NHL in
children and adolescents involves different histologies, primary sites of disease, patterns of
metastatic spread, approaches to therapy, and responses to treatment compared with adult NHL.
However, there are no standardized response criteria specific to pediatric NHL. Therefore, we
developed international standardized methods for assessing response to therapy in children and
adolescents with NHL.
Methods
An international multidisciplinary group of pediatric oncologists, pathologists, biologists, and
radiologists convened during and after the Third and Fourth International Childhood, Adolescent
and Young Adult NHL Symposia to review existing response and outcome data, develop methods
for response evaluation that reflect incorporation of more sensitive technologies currently in use,
and incorporate primary and metastatic sites of disease for the evaluation of therapeutic response
in children and adolescents with NHL.
Results
Using the current adult NHL response criteria as a starting point, international pediatric NHL
response criteria were developed incorporating both contemporary diagnostic imaging and
pathology techniques, including novel molecular and flow cytometric technologies used for the
determination of minimal residual disease.
Conclusion
Use of the international pediatric NHL response criteria in children and adolescents receiving
therapy for NHL incorporates data obtained from new and more sensitive technologies that are
now being widely used for disease evaluation, providing a standardized means for reporting
treatment response.
J Clin Oncol 33:2106-2111. © 2015 by American Society of Clinical Oncology
INTRODUCTION
There have been well-established response criteria
for adults with non-Hodgkin lymphoma (NHL).1,2
In the recently published Lugano classification sys-
tem, Barrington et al3 and Cheson et al4 updated and
reported revised response criteria during and after
treatment in adults with NHL. Both the prior and
more recent reports on therapy response assessment
in patients with NHL were developed without input
from the pediatric oncology community and did not
reference specific pediatric NHL disease entities.1-4
However, there are major differences in clinical pre-
sentation, pathologic subtype, approach to therapy,
and evaluation of response to treatment between
pediatric and adult NHLs.5-16 Currently, there are
no uniformly agreed on response evaluation criteria
for children with NHL. This dilemma prompted an
international effort to establish uniform criteria.
This proposal represents the consensus of a multi-
disciplinary international (North America, Europe,
and Australia) collaboration of experts in pediatric
oncology, hematopathology, radiology, and NHL
biology (Third and Fourth International Symposia
on Childhood, Adolescent and Young Adult NHL,
held in 2009 and 2012, respectively).
The International Harmonization Project con-
vened to address these issues in adults with malig-
nant lymphoma, and this group subsequently
published its recommendations.1,2 The more recent
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Lugano classification system incorporates [18F]fluorodeoxyglucose
(FDG) positron emission tomography (PET) findings, immunohisto-
chemistry (IHC) results, and flow cytometric data into response eval-
uation.3,4 The Lugano classification does not specify an age range for
intended application, but it is based on data primarily derived from
populations of adult patients with lymphoma. However, there are
some striking pathologic and staging differences between NHL occur-
ring in children and adolescents compared with adults. The spectrum
of histologic subtypes occurring in children and adolescents is quite
different than that observed in adults, with a predominance of high-
grade lymphomas occurring in children and adolescents.5,7,8,14,16
Children are more likely to present with extranodal disease and have a
greater propensity for involvement of the bone marrow (BM) and
CNS as compared with adults. However, detection of extranodal dis-
ease in kidneys or CNS or diffuse BM involvement can be difficult
using FDG-PET alone.17 With respect to response evaluation modal-
ities, the data on FDG-PET in pediatric NHL are derived from rela-
tively small patient cohorts, particularly with respect to residual
masses. However, there is increasingly wider use and acceptance of
more sensitive ancillary immunophenotypic and molecular ap-
proaches to quantify minimal residual disease (MRD) for the NHL
subtypes frequently encountered in children (eg, lymphoblastic lym-
phoma [LL], Burkitt’s lymphoma [BL], anaplastic large-cell lym-
phoma [ALCL]).18-24
The accuracy and precision of response evaluation are directly
related to the sensitivity, specificity, and availability of the tools used to
make the determination. This has clearly changed and evolved over
the years.24 Subsequent changes have included the use of FDG-PET
(available since early 2000s at some pediatric cancer centers), which in
most settings has replaced gallium and bone scintigraphy.25
There remains controversy on how to interpret FDG-PET findings
in children.17,25,26 A subcommittee of the International Harmonization
ProjectmadespecificrecommendationsregardingtheuseofFDG-PETin
adults with NHL, indicated that visual assessment alone using the medi-
astinal blood pool as a comparator is adequate for determining abnormal
FDG uptake, and strongly encouraged the implementation of the
attenuation-correction PET technique.27,28 These criteria for FDG-PET
assessment were intended for end-of-treatment evaluation, and it was
recommendedthattheuseofFDG-PETfortreatmentmonitoringduring
therapy be limited to clinical trials or prospective registries. Dunleavy et
al27 also emphasized that the role of FDG-PET is still being defined and
made the following observations and recommendations: 1) reports of
interim FDG-PET results in the treatment of adults with diffuse large
B-cell lymphoma (DLBCL) have prognostic significance; 2) using FDG-
PET to guide therapeutic decision making is still under investigation; 3)
there are a lack of standardized reporting criteria for FDG-PET with
proven reproducibility; and 4) interim FDG-PET should be considered
investigationalandonlyusedforclinicaldecisionmakinginthecontextof
a clinical trial. There are also conflicting reports regarding the predictive
valueofFDG-PETwithrespect totreatmentoutcome.29,30 Morerecently,
Barrington et al3 reported a new set of recommendations on the use of
PET–computed tomography (CT) for staging and response assessment
in malignant lymphomas to be used in clinical practice and late-phase
clinical trials. These recommendations have been incorporated into the
new Lugano classification and are intended both for interim analysis to
assessearlytreatmentresponseandforend-of-treatmentanalysistoestab-
lishremissionstatus.4 FormetabolicresponseassessmentonFDG-PETin
the Lugano classification, a visual 5-point scale based on the Deauville
criteria is recommended to grade the most intense disease FDG uptake,
with a score of 1 representing no uptake above background, a score of 2
representing uptakemediastinum, a score of 3 representing uptake
mediastinum but  liver, a score of 4 representing uptake moderately
higher than liver, and a score of 5 representing uptake markedly higher
than liver and/or new lesions.31 A score of 1 or 2 represents a complete
metabolic response, a score of 3 probably represents complete response
(CR) but may be considered as an inadequate response to avoid under-
treatment in a de-escalation trial, a score of 4 or 5 with reduced uptake
comparedwithbaselinerepresentsapartialmetabolic response,a scoreof
4 or 5 with no significant change from baseline represents no response,
and a score of 4 or 5 with an increase in uptake from baseline represents
progressive metabolic disease.4 However, it should be noted that the
Deauville criteria were developed and validated on the basis of studies
focused on adult DLBCL and follicular lymphoma subtypes and not
pediatric NHL subtypes.3
Experience with FDG-PET imaging in pediatric NHL is relatively
sparse compared with adult NHL. Riad et al32 described a small series of
children with BL who were found to have false-positive FDG-PET scans.
False-positive FDG-PET scans have been observed in children with be-
nign inflammatory processes,32 xanthomatous pseudotumour,33 brown
fat, rebound thymic hyperplasia, or infection or as the result of a granulo-
cyte colony-stimulating factor effect. A review of the past decade of pub-
lications regarding the use of FDG-PET for therapy response in pediatric
lymphoma showed that FDG-PET generally demonstrates high sensitiv-
ity and negative predictive value but more variable and modest positive
predictive value. Consequently, the significance of new or residual FDG-
avid foci in the absence of a growing nodal or extranodal mass on CT or
magnetic resonance imaging (MRI) is uncertain.34 Minimal residual
FDG-PET uptake has been the subject of much study and poses a chal-
lenge in the interpretation of FDG-PET.31,35-39 These studies have been
conducted primarily in adults, and specific data regarding FDG-PET
imagingtodetermineresponseinchildrenwithNHLundergoingtherapy
are relatively lacking because of small sample sizes and inconsistent study
designs.Arecentsmall studyshowedthatFDG-PETinterpretedusingthe
Deauville criteria can help confirm a CR in children with BL at the end of
induction chemotherapy by virtue of a high negative predictive value.40
However, with regard to the evaluation of treatment response in children
with BL or other NHL histologies, more data regarding the signif-
icance of FDG-PET findings in a residual mass is needed before
negative findings can be assumed to confirm a CR, as is now the
case in the newly proposed Lugano classification for adult PET-
CT– based response determination.2,4
MRI is the preferred imaging modality for evaluating CNS dis-
ease. CT scan is superior for assessing the lungs, and MRI is superior
for assessing the marrow. With growing concern about the risks of
cumulative ionizing radiation exposure to children resulting from CT,
MRI could be considered as an alternative to CT for evaluating
nonpulmonary disease sites, particularly in children with syndromes
associated with increased sensitivity to ionizing radiation (eg, ataxia-
telangiectasia, Nijmegen breakage syndrome).41
METHODS
Response criteria and methodology for determining response were reviewed
from the results of multiple childhood and adolescent NHL pediatric cooper-
ative group clinical trials and reports.5-16,42-44 Morphologic evaluation of a
pathologic sample, including a biopsy of a residual mass, or analysis of a BM or
Response Criteria in Pediatric NHL
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CSF sample remains the standard approach to determine response. However,
the findings of more sensitive pathologic techniques, including sensitive mo-
lecular and immunophenotypic approaches, should be considered and, in
some cases, used to define the response evaluation. For example, immunophe-
notyping by IHC or flow cytometric analysis is useful for determining whether
suspicious cells are in fact lymphoma. For example, in ALCL, occasional large
cells that are CD30 and/or ALK positive in a biopsy or BM sample may be
considered residual disease, assuming the diagnostic sample is also positive for
both markers.45,46 Similarly, use of sensitive flow cytometric approaches are
well accepted for detection of MRD in LL in blood and marrow.16 Use of other
more sensitive detection methods to identify residual disease is more contro-
versial, particularly in cases where suspicious cells are not observed in biopsy
materials. For example, positive cytogenetic findings from a tumor biopsy or
BM sample are not used to indicate induction failure, but we would advocate
that such findings should be indicated in the response designation as support-
ing data. The finding of positive cytogenetics is unusual in the setting of
negative morphologic evidence of disease. However, MRD testing (by either
flow cytometric or molecular method), which can detect one in 10,000 to one
in 100,000 cells, is more commonly observed, and inclusion of these data is not
required or considered in the current standard NHL response evaluation
systems in the literature. MRD technology has been successfully developed for
the major pediatric NHL subtypes.18-23 This includes flow cytometric deter-
mination of MRD for precursor T-LL,18 polymerase chain reaction (PCR)
detection of immunoglobulin gene rearrangements for mature B-cell lympho-
mas (eg, BL, DLBCL),22,23 and quantitative PCR screening for the NPM-
ALK fusion transcript in t(2;5)-positive cases of ALCL.19,20 If positive
MRD results are obtained, we do not recommend that the major response
evaluation category be changed (eg, from CR to partial response [PR]), but
we do suggest that this information be included in the response description
as supporting data.
RESULTS
International Pediatric NHL Response Criteria
On the basis of a review of scientific evidence, consensus among
the experts of this panel, recommendations of the International Har-
monization Project in Lymphoma, and more recent revised response
criteria,1-4 we propose the following criteria for response assessment in
children and adolescents receiving treatment for NHL (Table 1). We
have elected to use the change in the sum of the products of the largest
diameter and the perpendicular diameter (SPD) for each tumor mass,
as measured by CT or MRI, as the measure of tumor size change, with
the understanding that there may be cases where this is somewhat
imprecise because of irregularly shaped tumor masses or disseminated
disease with multiple tumor masses (Table 1). In cases with multiple
masses, up to six of the most representative nodal or extranodal masses
should be selected for measurement, as suggested in the new Lugano
classification for adults.1-4 To grade FDG uptake for metabolic re-
sponse assessment on PET, a reproducible method should be used,
such as the Deauville criteria visual 5-point scale recommended in the
Lugano classification4 or a more quantitative measure like the change
in the maximum standardized uptake value. This will facilitate analysis
and potential validation of these methods in subsequent clinical trials
of pediatric NHL.
CR
The CR designation will be used to indicate the disappearance of
all disease; however, there will be subclassification of this designation
to indicate how this designation was determined.
CR. The CR designation indicates the complete disappearance
of all disease, as confirmed by physical examination, CT, or MRI and
examination of CSF and BM. Specifically, the CT or MRI should be
free of residual mass or evidence of new disease. FDG-PET should be
negative (Deauville criteria score of 1, 2, or 3 [unless score of 3 is
considered as inadequate response to avoid undertreatment, such as in
de-escalation trial]). If a residual or new mass is present but has been
completely resected and is negative for disease by pathologic evalua-
tion of morphology, a CR designation is still assigned. Evaluation of
BM and CSF should be negative for morphologic evidence of disease
Table 1. International Pediatric NHL Response Criteria
Criterion Definition
CR Disappearance of all disease (three designations)
CR CT or MRI reveals no residual disease or new lesions
Resected residual mass that is pathologically (morphologically) negative for disease (detection of disease with more sensitive techniques described
as supporting data [Table 2])
BM and CSF morphologically free of disease (detection of disease with more sensitive techniques described as supporting data [Table 2])
CRb Residual mass has no morphologic evidence of disease from limited or core biopsy (detection of disease with more sensitive techniques
described as supporting data [ Table 2]), with no new lesions by imaging examination
BM and CSF morphologically free of disease (detection of disease with more sensitive techniques described as supporting data [ Table 2])
No new and/or progressive disease elsewhere
CRu Residual mass is negative by FDG-PET; no new lesions by imaging examination
BM and CSF morphologically free of disease (detection of disease with more sensitive techniques described as supporting data [Table 2])
No new and/or progressive disease elsewhere
PR 50% decrease in SPD on CT or MRI; FDG-PET may be positive (Deauville score or 4 or 5 with reduced lesional uptake compared with baseline);
no new and/or PD; morphologic evidence of disease may be present in BM or CSF if present at diagnosis (detection of disease with more
sensitive techniques described as supporting data [Table 2]); however, there should be 50% reduction in percentage of lymphoma cells
MR Decrease in SPD  25% but  50% on CT or MRI; no new and/or PD; morphologic evidence of disease may be present in BM or CSF if present
at diagnosis (detection of disease with more sensitive techniques described as supporting data [Table 2]); however, there should be 25% to
50% reduction in percentage of lymphoma cells
NR For those who do not meet CR, PR, MR, or PD criteria
PD For those with  25% increase in SPD on CT or MRI, Deauville score 4 or 5 on FDG-PET with increase in lesional uptake from baseline, or
development of new morphologic evidence of disease in BM or CSF
Abbreviations: BM, bone marrow; CR, complete response; CRb, complete response biopsy negative; CRu, complete response unconfirmed; CT, computed
tomography; FDG, [18F]fluorodeoxyglucose; MR, minor response; MRI, magnetic resonance imaging; NHL, non-Hodgkin lymphoma; NR, no response; PD,
progressive disease; PET, positron emission tomography; PR, partial response; SPD, sum of product of greatest perpendicular diameters.
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as well for the CR designation. Detection of disease using more sensi-
tive techniques, such as immunophenotyping or molecular tech-
niques should be indicated as supporting data, as summarized in Table
2. There should be no new and/or progressive disease (PD) elsewhere.2
CRbiopsynegative. The CR biopsy negative (CRb) designation is
for patients who otherwise meet the CR designation but have a resid-
ual mass on CT or MRI that is biopsied (not resected) and found to be
negative for disease based on pathologic evaluation of morphology. If
disease is detected by more sensitive tools (eg, molecular techniques,
flow cytometry, IHC, cytogenetics), this should be indicated as sup-
porting data, as summarized in Table 2. Although a biopsy of a resid-
ual mass that is negative for viable tumor provides some reassurance,
there is always a possibility of sampling error. Thus, a CRb designation
is included until there are more data showing that a negative biopsy is
equivalent to a negative morphologic examination of a completely
resected residual mass and/or until there are adequate PET data to
confidently exclude the need for biopsy of a PET-negative residual
mass. The decision to biopsy an FDG-PET–positive bone lesion is a
clinical judgment based on symptoms and level of concern about risk
associated with biopsy of a weight-bearing long bone.
CRunconfirmed. The CR unconfirmed designation is applied in
otherwise CR cases in which a residual mass on CT or MRI is negative
by FDG-PET imaging. BM and CSF must be morphologically negative
for tumor. There should be no new and/or PD elsewhere.
PR. The PR designation is assigned when there has been 50%
decrease in the SPD by CT or MRI. The FDG-PET imaging results
may be positive (Deauville score of 4 or 5 with reduced lesional
uptake compared with baseline). Morphologic detection of disease
in a biopsy sample of the mass may be present. There may also be
persistent morphologic detection of disease in the BM and CSF if
this finding was present at diagnosis; however, there should be a
50% reduction in the percentage of lymphoma cells. There should
be no new and/or PD elsewhere.
Minor response. The minor response designation is assigned in
cases where the decrease in the SPD is 25% but 50%. Morpho-
logic detection of disease in a biopsy sample of the mass may be
present. There may also be persistent morphologic detection of disease
in the BM and CSF, if this finding was present at diagnosis; however,
there should be a 25% to 50% reduction in the percentage of lym-
phoma cells. There should be no new and/or PD elsewhere.
No response. The no response designation will be applied for
those patients whose residual lesions do not meet the criteria for CR,
PR, minor response, or PD.
PD. The PD designation is applied for any patient with 25%
increase in the SPD of residual lesions, Deauville score 4 or 5 on
FDG-PET with an increase in lesional uptake from baseline, or docu-
mentation of new lesions. PD also applies to any patient who develops
new morphologic evidence of BM or CNS disease.
Supporting Response Data
The recommended collection of additional response data beyond
current conventional data collection is summarized in Table 2. These
additional data largely reflect information obtained using newer or
more sensitive technologies to detect MRD. Although these data are
not incorporated into our recommended response evaluation criteria
outlined in this report, they will likely be used in future recommenda-
tions for pediatric NHL response evaluation.
DISCUSSION
The international pediatric NHL response criteria described in this
consensus statement provide a more uniform and accurate means of
defining treatment response in children and adolescents with NHL
and allow for systematic collection of supporting data generated by
ancillary testing (Table 2) that may, in the future, become important
criteria in defining response. The major response designations will be
established by CT or MRI of involved sites in conjunction with mor-
phologic evaluation of BM and CSF, if involved at diagnosis. With
growing concern about the risks of cumulative ionizing radiation
Table 2. Supporting International Pediatric NHL Response Criteria Data
Supporting
Information Description
BM involvement Currently defined by morphologic evidence of lymphoma cells; this applies to any histologic subtype; type and degree of BM involvement
should be specified
BMm BM positive by morphology (specify percentage of lymphoma cells)
BMi BM positive by immunophenotypic methods (histochemical or flow cytometric analysis; specify percentage of lymphoma cells)
BMc BM positive by cytogenetic or FISH analysis (specify percentage of lymphoma cells)
BMmol BM positive by molecular techniques
CNS involvement
CSF status CSF positivity is based on morphologic evidence of lymphoma cells; CSF should be considered positive when any number of blasts is
detected; CSF may be unknown; as with BM, type of CSF involvement should be described whenever possible
CSFm CSF positive by morphology (specify No. of blasts/L)
CSFi CSF positive by immunophenotype methods (histochemical or flow cytometric analysis; specify percentage of lymphoma cells)
CSFc CSF positive by cytogenetic or FISH analysis (specify percentage of lymphoma cells)
CSFmol CSF positive by molecular techniques
RM
RMm Tumor detected by standard morphologic evaluation
RMi Tumor detected by immunophenotypic methods (immunohistochemical or flow cytometric analysis)
RMc Tumor detected by cytogenetic or FISH analysis
RMmol Tumor detected by molecular techniques
Abbreviations: BM, bone marrow; FISH, fluorescent in situ hybridization; NHL, non-Hodgkin lymphoma; PB, peripheral blood; RM, residual mass.
Same approach should be used for PB involvement (ie, PBm, PBi, PBc, PBmol).
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exposure to children resulting from CT, MRI could be considered as
an alternative to CT for evaluating nonpulmonary disease sites. The
lack of universal availability of FDG-PET is accounted for in this
system; however, in centers where FDG-PET is available, the results
will be used and designated accordingly.
This response evaluation system will be revised as additional
evidence about the utility, reproducibility, and impact of data from
FDG-PET and more advanced immunophenotypic and molecular
tools become available. For example, the need for a CR unconfirmed
designation may become unnecessary (as in revised Cheson criteria
and Lugano classification),2-4 if sufficient evidence becomes available
that FDG-PET–negative masses reflect a true CR in children and
adolescents with NHL. Pathologic evaluation of a residual FDG-PET–
negative mass provides the most direct evidence as to whether a true
CR has been achieved, whereas lack of progression or relapse at the site
of the residual FDG-PET–negative mass would provide indirect evi-
dence of CR status. More sensitive molecular and immunophenotypic
tools for disease detection will also be helpful in further refining
response criteria. Among children with acute lymphoblastic leukemia,
MRD as detected by PCR or flow cytometry is now reported as a
subdesignation of response in marrows that are otherwise morpho-
logically free of disease.47,48 Similarly, MRD evaluations of peripheral
blood and BM in NHL are now possible for children and adolescents
with the major pediatric lymphoma subtypes,18,19,21-23 and this infor-
mation can now be included in the description of response evaluation
as supportive data. Additional refinements in the description of re-
sponse evaluation will be required as more sensitive tools are devel-
oped for pathologic detection of disease and evidence as to their utility
in defining outcomes emerges.
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